Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo

Targeted delivery and controlled release of inactive platinum (Pt) prodrugs may offer a new approach to improve the efficacy and tolerability of the Pt family of drugs, which are used to treat 50% of all cancers today. Using prostate cancer (PCa) as a model disease, we previously described the engin...

Full description

Bibliographic Details
Main Authors: Dhar, Shanta (Contributor), Kolishetti, Nagesh (Contributor), Lippard, Stephen J. (Contributor), Farokhzad, Omid C. (Contributor)
Other Authors: MIT-Harvard Center for Cancer Nanotechnology Excellence (Contributor), Massachusetts Institute of Technology. Department of Chemistry (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: National Academy of Sciences (U.S.), 2011-08-11T19:30:11Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items